AXSM · Axsome Therapeutics Inc
United States · RS rating 20 · As of 2026-11-03
| Price | 139.61 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 20 / 20 / 17 / 54 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 40 / 17 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +40.4% |
| Sales growth Q/Q | +14.6% |
| Distance from 52-week high | +45.3% |
| Market cap (USD) | $9.3B |